Destiny Pharma
Skip to content
  • Home
  • Company
    • Our Focus
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Vision
  • Need
    • Antibiotic Resistance
    • Post Surgical Infections
    • Incentives for New Antibacterial Drugs
    • Societal Cost
    • Links
  • Platform
    • XF Drug Series
    • XF-73 (exeporfinium chloride)
    • Pipeline
  • Market
  • Investors
    • AIM Rule 26
    • Share Price
    • Regulatory News
    • Company Information
    • Documents
    • Reports & Presentations
    • Advisers
    • Analyst Coverage
    • Corporate Governance
  • News
    • Regulatory news – News
  • Contact
    • Careers
News & Events

Revolutionary Superbug Treatment

 

Continue Reading

Month: December 2013

Destiny Pharma to attend 32nd Annual J.P. Morgan Healthcare Conference, San Francisco

Posted on 20/12/2013 by briteadmin

Destiny Pharma today announced that Dr Bill Love, Chief Executive Officer, will be attending the 32nd Annual J.P. Morgan Healthcare Conference, to be held on 13-16th January in San Francisco. If you are attending the conference and would like to book an appointment to meet with Dr Love please email us on kr@destinypharma.com.

Posted in Uncategorised
Leave a comment

Latest News

  • Neil Clark, CEO, interviewed at Proactive Investor event on 28 January 2019 30/01/2019
  • Second positive Phase 1 trial data for XF-73 28/01/2019
  • Destiny awarded new UK-China AMR grant 25/01/2019
  • Destiny Pharma notes UK 5-year action plan on AMR 24/01/2019

Events

  • Destiny Pharma to attend BIO-Europe Spring, 25 – 27 March 2019, Vienna, Austria 17/02/2019
  • Destiny Pharma to attend Superbugs & Superdrugs 2019, 18 – 19 March 2019, London, UK 17/01/2019
  • Destiny Pharma to attend Novel Antimicrobials and AMR Diagnostics 2019, 14 – 15 March 2019, Berlin, Germany 17/01/2019

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc.
Sussex Innovation Centre
Science Park Square
Falmer
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
Home
Company
Need
Platform
Market
Investors
News
Contact